SYRE Latest Headlines

Spyre Therapeutics Faces Ongoing Dilution Risk and Strategic Constraints From Heavy Reliance on External Financing

at www.tipranks.com (Thu, 5-Nov 1:00 AM)

Spyre Therapeutics: IBD Potential and IL-23 Programs Support Unchanged $130 Price Target Despite Rheumatology Setbacks

at www.tipranks.com (Wed, 4-Nov 4:05 PM)

Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE), Waters (WAT) and Tarsus Pharmaceuticals (TARS)

at www.tipranks.com (Wed, 4-Nov 4:00 PM)

Guggenheim Remains a Buy on Spyre Therapeutics (SYRE)

at www.tipranks.com (Wed, 4-Nov 8:55 AM)

Spyre’s $121 Price Target Unchanged as SKYLINE Progress and HS Potential Strengthen Outlook

at www.tipranks.com (Wed, 4-Nov 8:39 AM)

Spyre Therapeutics GAAP EPS of -$0.94 misses by $0.11

at seekingalpha.com (Tue, 3-Nov 4:49 PM)

Big Pharma Has $1.2 Trillion to Spend and a Revenue Gap to Fill: Inside the F/m Emerald Life Sciences Innovation ETF (LFSC)

at www.tipranks.com (Mon, 2-Nov 7:00 AM)

Spyre Therapeutics prices $350 million offering at $85 a share, adding a 30-day option for up to $52.5 million more

Market Chameleon (Tue, 6-Oct 7:08 AM)